New hope for advanced cervical cancer: trial tests drug combo after standard treatment fails
NCT ID NCT06157151
Summary
This study is for people with advanced cervical cancer that has returned or spread and is no longer responding to the immunotherapy drug pembrolizumab. It will test if adding a new investigational drug called PRGN-2009 to pembrolizumab is more effective and safe than continuing pembrolizumab alone. About 46 participants will be randomly assigned to receive either the combination or the single drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institute of Health
RECRUITINGBethesda, Maryland, 20892, United States
Contact Email: •••••@•••••
-
University of Arkansas for Medical Sciences
RECRUITINGLittle Rock, Arkansas, 72205, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.